The growing importance of digital in healthcare is disrupting traditional medicine and medical device development cycles. Digital companies are developing their technology faster, and are bringing to market products that too often have not been demonstrated to have clinical value.  

The lack of evaluation and analysis of the potential of the market induces a significant risk: 

• It initiates the market access process
• It can lead projects to new R&D phases
• It can jeopardize the company when R&D funding is no longer assured

This action is linked to the experimentation axis of the strategy.

The goal is to support projects that aim to evaluate the benefit of digital or AI-based medical devices. The results of rigorous evaluation projects should:

• Allow to justify the use in practice of the tested device
• Determine access to common law, guaranteeing a recurrent business model for companies demonstrating a significant medical service rendered.
• To be the foundation of trust in these new technologies among users and citizens alike

Calls for projects will be launched in successive waves every year. A support mechanism will be implemented by the health departments.